anti glucose 6 phosphate dehydrogenase  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc anti glucose 6 phosphate dehydrogenase
    Anti Glucose 6 Phosphate Dehydrogenase, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti glucose 6 phosphate dehydrogenase/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti glucose 6 phosphate dehydrogenase - by Bioz Stars, 2023-11
    86/100 stars

    Images

    glucose 6 phosphate dehydrogenase  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc glucose 6 phosphate dehydrogenase
    Metabolic reprogramming in Lal -/- Ly6G + cells. (A) The tSNE plot of genes involved in glycolysis in Lal -/- versus Lal +/+ Ly6G + cells. (B) The tSNE plot of genes involved in the citrate cycle in Lal -/- versus Lal +/+ Ly6G + cells. (C) The tSNE plot of genes responding to ROS in Lal -/- versus Lal +/+ Ly6G + cells. In (A), (B) and (C), green dots represent cluster 123, red dots represent cluster 0468, and blue dots represent other clusters. (D) Expressions of metabolic enzymes in Lal -/- versus Lal +/+ Ly6G + cells by western blot analysis. (E) Levels of glucose, pyruvate, and α-ketoglutarate in Lal -/- versus Lal +/+ Ly6G + cells. Data are expressed as mean±SD; experiments were independently repeated, n=4. *p<0.05, **p<0.01. <t>G6PD,</t> <t>glucose-6-phosphate</t> dehydrogenase; GLUD, glutamate dehydrogenase; HK, hexokinase; KO, knockout; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; tSNE, T-stochastic neighbor embedding; WT, wild type.
    Glucose 6 Phosphate Dehydrogenase, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glucose 6 phosphate dehydrogenase/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glucose 6 phosphate dehydrogenase - by Bioz Stars, 2023-11
    95/100 stars

    Images

    1) Product Images from "LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer"

    Article Title: LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

    Journal: Journal for Immunotherapy of Cancer

    doi: 10.1136/jitc-2022-006272

    Metabolic reprogramming in Lal -/- Ly6G + cells. (A) The tSNE plot of genes involved in glycolysis in Lal -/- versus Lal +/+ Ly6G + cells. (B) The tSNE plot of genes involved in the citrate cycle in Lal -/- versus Lal +/+ Ly6G + cells. (C) The tSNE plot of genes responding to ROS in Lal -/- versus Lal +/+ Ly6G + cells. In (A), (B) and (C), green dots represent cluster 123, red dots represent cluster 0468, and blue dots represent other clusters. (D) Expressions of metabolic enzymes in Lal -/- versus Lal +/+ Ly6G + cells by western blot analysis. (E) Levels of glucose, pyruvate, and α-ketoglutarate in Lal -/- versus Lal +/+ Ly6G + cells. Data are expressed as mean±SD; experiments were independently repeated, n=4. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; HK, hexokinase; KO, knockout; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; tSNE, T-stochastic neighbor embedding; WT, wild type.
    Figure Legend Snippet: Metabolic reprogramming in Lal -/- Ly6G + cells. (A) The tSNE plot of genes involved in glycolysis in Lal -/- versus Lal +/+ Ly6G + cells. (B) The tSNE plot of genes involved in the citrate cycle in Lal -/- versus Lal +/+ Ly6G + cells. (C) The tSNE plot of genes responding to ROS in Lal -/- versus Lal +/+ Ly6G + cells. In (A), (B) and (C), green dots represent cluster 123, red dots represent cluster 0468, and blue dots represent other clusters. (D) Expressions of metabolic enzymes in Lal -/- versus Lal +/+ Ly6G + cells by western blot analysis. (E) Levels of glucose, pyruvate, and α-ketoglutarate in Lal -/- versus Lal +/+ Ly6G + cells. Data are expressed as mean±SD; experiments were independently repeated, n=4. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; HK, hexokinase; KO, knockout; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; tSNE, T-stochastic neighbor embedding; WT, wild type.

    Techniques Used: Western Blot, Knock-Out, Derivative Assay

    Expressions of metabolic enzymes in NSCLC versus healthy subjects. (A) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in the whole blood cells. (B) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC versus healthy individuals. (C) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells. (D) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC versus healthy individuals. (E) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC versus healthy individuals. Data are expressed as mean±SD; experiments were independently repeated, n=9–13. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PDH, pyruvate dehydrogenase.
    Figure Legend Snippet: Expressions of metabolic enzymes in NSCLC versus healthy subjects. (A) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in the whole blood cells. (B) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC versus healthy individuals. (C) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells. (D) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC versus healthy individuals. (E) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC versus healthy individuals. Data are expressed as mean±SD; experiments were independently repeated, n=9–13. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PDH, pyruvate dehydrogenase.

    Techniques Used:

    Checkpoint inhibitor treatment. (A) Statistical analysis of percentages of PD-L1 + cells in leucocytes of patients with NSCLC before versus after treatment. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes of patients with NSCLC before versus after treatment. (C) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (D) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC before versus after treatment. (E) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (F) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC before versus after treatment. Data are expressed as mean±SD; experiments were independently repeated, n=5–9. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; PDH, pyruvate dehydrogenase.
    Figure Legend Snippet: Checkpoint inhibitor treatment. (A) Statistical analysis of percentages of PD-L1 + cells in leucocytes of patients with NSCLC before versus after treatment. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes of patients with NSCLC before versus after treatment. (C) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (D) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC before versus after treatment. (E) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (F) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC before versus after treatment. Data are expressed as mean±SD; experiments were independently repeated, n=5–9. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; PDH, pyruvate dehydrogenase.

    Techniques Used:

    anti g6pd  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc anti g6pd
    Dampened expression of glucose-6-phosphate dehydrogenase <t>(G6PD)</t> impairs spontaneous recovery of glutathione oxidation and NADPH following ISOPOOH exposure of HAEC. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD KD HAEC expressing Grx1-roGFP2 (A) or iNAP1 (B). G6PD KD HAEC were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 5–6 independent experiments where the responses from 10 individual cells were averaged for each experiment.
    Anti G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti g6pd/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti g6pd - by Bioz Stars, 2023-11
    95/100 stars

    Images

    1) Product Images from "Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide"

    Article Title: Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide

    Journal: Redox Biology

    doi: 10.1016/j.redox.2023.102646

    Dampened expression of glucose-6-phosphate dehydrogenase (G6PD) impairs spontaneous recovery of glutathione oxidation and NADPH following ISOPOOH exposure of HAEC. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD KD HAEC expressing Grx1-roGFP2 (A) or iNAP1 (B). G6PD KD HAEC were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 5–6 independent experiments where the responses from 10 individual cells were averaged for each experiment.
    Figure Legend Snippet: Dampened expression of glucose-6-phosphate dehydrogenase (G6PD) impairs spontaneous recovery of glutathione oxidation and NADPH following ISOPOOH exposure of HAEC. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD KD HAEC expressing Grx1-roGFP2 (A) or iNAP1 (B). G6PD KD HAEC were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 5–6 independent experiments where the responses from 10 individual cells were averaged for each experiment.

    Techniques Used: Expressing, Confocal Microscopy, Incubation, Fluorescence

    Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 and iNAP1 signal in glucose deprived  G6PD  KD HAEC as shown in <xref ref-type= Fig. 5 A and B, respectively." title="... in Grx1-roGFP2 and iNAP1 signal in glucose deprived G6PD KD HAEC as shown in
    Figure Legend Snippet: Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 and iNAP1 signal in glucose deprived G6PD KD HAEC as shown in Fig. 5 A and B, respectively.

    Techniques Used:

    A knockout of glucose-6-phosphate dehydrogenase (G6PD) in a BALB/c cell model impairs glucose-mediated recovery of glutathione oxidation following ISOPOOH exposure. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD knockout (A, C) or wild-type BALB/c cells (B, D), respectively. BALB/c cells expressing Grx1-roGFP2 (A, B) or iNAP1 (C, D) were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 3–5 independent experiments where the responses from 10 individual cells were averaged for each experiment.
    Figure Legend Snippet: A knockout of glucose-6-phosphate dehydrogenase (G6PD) in a BALB/c cell model impairs glucose-mediated recovery of glutathione oxidation following ISOPOOH exposure. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD knockout (A, C) or wild-type BALB/c cells (B, D), respectively. BALB/c cells expressing Grx1-roGFP2 (A, B) or iNAP1 (C, D) were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 3–5 independent experiments where the responses from 10 individual cells were averaged for each experiment.

    Techniques Used: Knock-Out, Confocal Microscopy, Expressing, Incubation, Fluorescence

    Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 signal in glucose deprived  G6PD  KO BALB/c and WT BALB/c cells as shown in <xref ref-type= Fig. 6 A and B, respectively." title="... glucose-mediated changes in Grx1-roGFP2 signal in glucose deprived G6PD KO BALB/c and WT BALB/c cells ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 signal in glucose deprived G6PD KO BALB/c and WT BALB/c cells as shown in Fig. 6 A and B, respectively.

    Techniques Used:

    Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in iNAP1 signal in glucose deprived  G6PD  KO BALB/c and WT BALB/c cells as shown in <xref ref-type= Fig. 6 C and D, respectively." title="... glucose-mediated changes in iNAP1 signal in glucose deprived G6PD KO BALB/c and WT BALB/c cells ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in iNAP1 signal in glucose deprived G6PD KO BALB/c and WT BALB/c cells as shown in Fig. 6 C and D, respectively.

    Techniques Used:

    8866s  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc 8866s
    Antibody list
    8866s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/8866s/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    8866s - by Bioz Stars, 2023-11
    94/100 stars

    Images

    1) Product Images from "A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells"

    Article Title: A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells

    Journal: Journal of Food and Drug Analysis

    doi: 10.38212/2224-6614.3376

    Antibody list
    Figure Legend Snippet: Antibody list

    Techniques Used: Western Blot

    g6pd  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc g6pd
    Gossypol enhances cisplatin sensitivity through inhibition of <t>NRF2/G6PD</t> axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).
    G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/g6pd/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    g6pd - by Bioz Stars, 2023-11
    94/100 stars

    Images

    1) Product Images from "A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells"

    Article Title: A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells

    Journal: Journal of Food and Drug Analysis

    doi: 10.38212/2224-6614.3376

    Gossypol enhances cisplatin sensitivity through inhibition of NRF2/G6PD axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).
    Figure Legend Snippet: Gossypol enhances cisplatin sensitivity through inhibition of NRF2/G6PD axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).

    Techniques Used: Inhibition, Expressing, Western Blot, Concentration Assay

    Antibody list
    Figure Legend Snippet: Antibody list

    Techniques Used: Western Blot

    glucose 6 phosphate dehydrogenase activity assay kit  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc glucose 6 phosphate dehydrogenase activity assay kit
    Glucose 6 Phosphate Dehydrogenase Activity Assay Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glucose 6 phosphate dehydrogenase activity assay kit/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glucose 6 phosphate dehydrogenase activity assay kit - by Bioz Stars, 2023-11
    95/100 stars

    Images

    g6pd  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc g6pd
    Modulation of NSC59984 effects by combination treatment with ROS regulators. (A) Fold change in total ROS levels (DCFDA) following treatment of ESO26-R248W cells with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) over carrier control. Fold change in carrier-treated cells was normalized to 1 (B) Fold change in total GSH level (µM GSH per µg of cellular protein) in ESO26-R248W cells treated with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) over carrier control. Fold change in carrier-treated cells was normalized to 1. (C) . ESO26-R248W cellular proliferation was measured following treatment with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM). Cells were re-seeded and fold change in CyQUANT quantitation of cellular DNA was measured following 5 days of growth over carrier control. Fold change in carrier-treated cells was normalized to 1. (D) Apoptosis in ESO26-R248W cells treated with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) as measured by change in percentage of Annexin V positive cells. Cells were re-seeded and the change in percent of Annexin V positive cells was assessed following 72 hr growth. (E) Effect of NSC59984 treatment on <t>G6PD</t> protein level. Shown is a representative image, whole cell lysate was blotted for G6PD expression following 8 hr treatment with NSC59984 (12 μM) in EAC cells. (F) Fold change in G6PD activity following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. Fold change in carrier-treated cells was normalized to 1. (G) Fold-change in total NADPH levels following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. (H) Western blot analysis of p53-p73 protein levels. ESO26 cells were treated with NSC59984 (12 μM) for 72 hr before cell lysis. Total protein was IP with p53 D01. Sample Input, IgG preclear, unbound protein controls and IP samples were blotted for p73. Fold change in carrier-treated cells was normalized to 1. (A-H). A 2-way ANOVA test with Tukey correction was carried out for statistical analysis for each of these assays. (I) ChIP analysis of the occupancy of p73 on the CaN19 promoter in carrier-treated cells or following 2 hr treatment with 12 μM NSC59984 in CP-A-WT or ESO26-R248W cells. ChIP was performed using the Active Motif ChIP-IT Express ® kit. Chromatin Input was diluted 1:100 before analysis (left), ChIP DNA was analyzed as percent of Input (right). A 2-way ANOVA with Šidák’s correction was carried out for statistical analysis. Raw Ct values can be found in <xref ref-type= Supplemental Table 2 . * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005. " width="250" height="auto" />
    G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/g6pd/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    g6pd - by Bioz Stars, 2023-11
    95/100 stars

    Images

    1) Product Images from "Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile"

    Article Title: Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2022.1094210

    Modulation of NSC59984 effects by combination treatment with ROS regulators. (A) Fold change in total ROS levels (DCFDA) following treatment of ESO26-R248W cells with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) over carrier control. Fold change in carrier-treated cells was normalized to 1 (B) Fold change in total GSH level (µM GSH per µg of cellular protein) in ESO26-R248W cells treated with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) over carrier control. Fold change in carrier-treated cells was normalized to 1. (C) . ESO26-R248W cellular proliferation was measured following treatment with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM). Cells were re-seeded and fold change in CyQUANT quantitation of cellular DNA was measured following 5 days of growth over carrier control. Fold change in carrier-treated cells was normalized to 1. (D) Apoptosis in ESO26-R248W cells treated with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) as measured by change in percentage of Annexin V positive cells. Cells were re-seeded and the change in percent of Annexin V positive cells was assessed following 72 hr growth. (E) Effect of NSC59984 treatment on G6PD protein level. Shown is a representative image, whole cell lysate was blotted for G6PD expression following 8 hr treatment with NSC59984 (12 μM) in EAC cells. (F) Fold change in G6PD activity following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. Fold change in carrier-treated cells was normalized to 1. (G) Fold-change in total NADPH levels following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. (H) Western blot analysis of p53-p73 protein levels. ESO26 cells were treated with NSC59984 (12 μM) for 72 hr before cell lysis. Total protein was IP with p53 D01. Sample Input, IgG preclear, unbound protein controls and IP samples were blotted for p73. Fold change in carrier-treated cells was normalized to 1. (A-H). A 2-way ANOVA test with Tukey correction was carried out for statistical analysis for each of these assays. (I) ChIP analysis of the occupancy of p73 on the CaN19 promoter in carrier-treated cells or following 2 hr treatment with 12 μM NSC59984 in CP-A-WT or ESO26-R248W cells. ChIP was performed using the Active Motif ChIP-IT Express ® kit. Chromatin Input was diluted 1:100 before analysis (left), ChIP DNA was analyzed as percent of Input (right). A 2-way ANOVA with Šidák’s correction was carried out for statistical analysis. Raw Ct values can be found in <xref ref-type= Supplemental Table 2 . * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005. " title="... hr growth. (E) Effect of NSC59984 treatment on G6PD protein level. Shown is a representative image, whole ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Modulation of NSC59984 effects by combination treatment with ROS regulators. (A) Fold change in total ROS levels (DCFDA) following treatment of ESO26-R248W cells with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) over carrier control. Fold change in carrier-treated cells was normalized to 1 (B) Fold change in total GSH level (µM GSH per µg of cellular protein) in ESO26-R248W cells treated with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) over carrier control. Fold change in carrier-treated cells was normalized to 1. (C) . ESO26-R248W cellular proliferation was measured following treatment with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM). Cells were re-seeded and fold change in CyQUANT quantitation of cellular DNA was measured following 5 days of growth over carrier control. Fold change in carrier-treated cells was normalized to 1. (D) Apoptosis in ESO26-R248W cells treated with NSC59984 (12 μM) for 24 hr either alone or in combination with NAC (1 mM) or BSO (10 mM) as measured by change in percentage of Annexin V positive cells. Cells were re-seeded and the change in percent of Annexin V positive cells was assessed following 72 hr growth. (E) Effect of NSC59984 treatment on G6PD protein level. Shown is a representative image, whole cell lysate was blotted for G6PD expression following 8 hr treatment with NSC59984 (12 μM) in EAC cells. (F) Fold change in G6PD activity following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. Fold change in carrier-treated cells was normalized to 1. (G) Fold-change in total NADPH levels following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. (H) Western blot analysis of p53-p73 protein levels. ESO26 cells were treated with NSC59984 (12 μM) for 72 hr before cell lysis. Total protein was IP with p53 D01. Sample Input, IgG preclear, unbound protein controls and IP samples were blotted for p73. Fold change in carrier-treated cells was normalized to 1. (A-H). A 2-way ANOVA test with Tukey correction was carried out for statistical analysis for each of these assays. (I) ChIP analysis of the occupancy of p73 on the CaN19 promoter in carrier-treated cells or following 2 hr treatment with 12 μM NSC59984 in CP-A-WT or ESO26-R248W cells. ChIP was performed using the Active Motif ChIP-IT Express ® kit. Chromatin Input was diluted 1:100 before analysis (left), ChIP DNA was analyzed as percent of Input (right). A 2-way ANOVA with Šidák’s correction was carried out for statistical analysis. Raw Ct values can be found in Supplemental Table 2 . * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005.

    Techniques Used: CyQUANT Assay, Quantitation Assay, Expressing, Activity Assay, Western Blot, Lysis

    NSC59984 treatment results in p53-dependent activation of TIGAR. (A) Fold change in PFK1 activity following treatment with NSC59984 (12 μM) for 72 hr over carrier control in ESO26-R248W cells. Fold change in carrier-treated cells was normalized to 1. A paired t-test was carried out for statistical analysis. (B) Fold changes in mRNA expression levels of TIGAR were analyzed by RT - qPCR following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. Fold change in carrier-treated cells was normalized to 1. Expression was normalized to β-actin. A 2-way ANOVA test with Tukey correction was carried out for statistical analysis. (C) Whole cell lysate was blotted for TIGAR expression following treatment with NSC59984 (12 μM) for 72 hr in the selected panel of EAC cells. (D) ChIP analysis of the occupancy of p53 on the TIGAR promoter in carrier-treated cells or following 2 hr treatment with 12 μM NSC59984 in CP-A-WT or ESO26-R248W cells. ChIP was performed using the Active Motif ChIP-IT Express ® kit. Chromatin Input was diluted 1:100 before analysis (left), ChIP DNA was analyzed as percent of Input (right). A 2-way ANOVA with Šidák’s correction was carried out for statistical analysis. Raw Ct values can be found in <xref ref-type= Supplemental Table 3 (E) Cellular proliferation in ESO26-R248W cells following treatment with NSC59984 (12 μM) for 72 hr over carrier control in siTIGAR or siControl cells. Proliferation was determined by change in CyQUANT measurement of cellular DNA. Fold change in carrier-treated cells was normalized to 1. A 2-way ANOVA test with Tukey correction was carried out for statistical analysis. (F) Western blot analysis of G6PD protein levels following treatment with NSC59984 (12 μM) for 72 hr in siTIGAR or siControl ESO26-R248W cells. * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005. " title="... for statistical analysis. (F) Western blot analysis of G6PD protein levels following treatment with NSC59984 (12 μM) ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: NSC59984 treatment results in p53-dependent activation of TIGAR. (A) Fold change in PFK1 activity following treatment with NSC59984 (12 μM) for 72 hr over carrier control in ESO26-R248W cells. Fold change in carrier-treated cells was normalized to 1. A paired t-test was carried out for statistical analysis. (B) Fold changes in mRNA expression levels of TIGAR were analyzed by RT - qPCR following treatment with NSC59984 (12 μM) for 72 hr over carrier control in EAC cells. Fold change in carrier-treated cells was normalized to 1. Expression was normalized to β-actin. A 2-way ANOVA test with Tukey correction was carried out for statistical analysis. (C) Whole cell lysate was blotted for TIGAR expression following treatment with NSC59984 (12 μM) for 72 hr in the selected panel of EAC cells. (D) ChIP analysis of the occupancy of p53 on the TIGAR promoter in carrier-treated cells or following 2 hr treatment with 12 μM NSC59984 in CP-A-WT or ESO26-R248W cells. ChIP was performed using the Active Motif ChIP-IT Express ® kit. Chromatin Input was diluted 1:100 before analysis (left), ChIP DNA was analyzed as percent of Input (right). A 2-way ANOVA with Šidák’s correction was carried out for statistical analysis. Raw Ct values can be found in Supplemental Table 3 (E) Cellular proliferation in ESO26-R248W cells following treatment with NSC59984 (12 μM) for 72 hr over carrier control in siTIGAR or siControl cells. Proliferation was determined by change in CyQUANT measurement of cellular DNA. Fold change in carrier-treated cells was normalized to 1. A 2-way ANOVA test with Tukey correction was carried out for statistical analysis. (F) Western blot analysis of G6PD protein levels following treatment with NSC59984 (12 μM) for 72 hr in siTIGAR or siControl ESO26-R248W cells. * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005.

    Techniques Used: Activation Assay, Activity Assay, Expressing, Quantitative RT-PCR, CyQUANT Assay, Western Blot

    Schematic detailing the effects of p53 stabilization on metabolic pathways. The stabilization of the p53 structure upon treatment with NSC59984 initiates a cascade of effects through both transcriptional- and non-transcriptional regulation. Via transcriptional regulation, stabilized p53 increases expression of TIGAR which causes a subsequent reduction of PFK and blocks glycolysis. A concurrent increase in G6PD potentially mediated by p73 having been released from an inhibitory complex with mutant p53 (dashed line) allows the processing of glucose to flow through the PPP via increased HK and Glucose-6P. This reduces cellular energetics and subsequently cellular proliferation. Simultaneously, a transcriptional increase in Bax allows increased cytochrome C release from the mitochondria with ensuing intrinsic apoptosis. Labels in BOLD indicate measured increases following treatment with NSC59984. * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005.
    Figure Legend Snippet: Schematic detailing the effects of p53 stabilization on metabolic pathways. The stabilization of the p53 structure upon treatment with NSC59984 initiates a cascade of effects through both transcriptional- and non-transcriptional regulation. Via transcriptional regulation, stabilized p53 increases expression of TIGAR which causes a subsequent reduction of PFK and blocks glycolysis. A concurrent increase in G6PD potentially mediated by p73 having been released from an inhibitory complex with mutant p53 (dashed line) allows the processing of glucose to flow through the PPP via increased HK and Glucose-6P. This reduces cellular energetics and subsequently cellular proliferation. Simultaneously, a transcriptional increase in Bax allows increased cytochrome C release from the mitochondria with ensuing intrinsic apoptosis. Labels in BOLD indicate measured increases following treatment with NSC59984. * = 0.05, ** = 0.005, *** = 0.0005, **** = 0.00005.

    Techniques Used: Expressing, Mutagenesis

    glucose 6 phosphate dehydrogenase  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc glucose 6 phosphate dehydrogenase
    Glucose 6 Phosphate Dehydrogenase, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glucose 6 phosphate dehydrogenase/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glucose 6 phosphate dehydrogenase - by Bioz Stars, 2023-11
    86/100 stars

    Images

    g6pd  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc g6pd
    Genes from each cluster assembled in networks and their top functions/canonical pathways. Gene names in bold are
    G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/g6pd/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    g6pd - by Bioz Stars, 2023-11
    95/100 stars

    Images

    1) Product Images from "Systems biology approach for mapping the response of human urothelial cells to infection by Enterococcus faecalis"

    Article Title: Systems biology approach for mapping the response of human urothelial cells to infection by Enterococcus faecalis

    Journal: BMC Bioinformatics

    doi: 10.1186/1471-2105-8-S7-S2

    Genes from each cluster assembled in networks and their top functions/canonical pathways. Gene names in bold are
    Figure Legend Snippet: Genes from each cluster assembled in networks and their top functions/canonical pathways. Gene names in bold are "focus genes" identified as VHV and served to identify key elements in hypothetical networks constructed by IPA. Statistically significant top functions and canonical pathways are identified by IPA. Hypothetical networks identified by IPA as being potentially present were pruned to remove genes that were not identified as being expressed.

    Techniques Used: Construct, Infection, Expressing, Coagulation, Cell Function Assay

    g6pd  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc g6pd
    (A) <t>G6PD</t> activity of HUVECs with different treatments. **p<.01 vs. NC group. (B) mRNA level of G6PD with different treatments. **p<.01 vs. NC group (C) Western-blot analysis shows that G6PD expression decreased with G6PD siRNA. (D) G6PD activity decreases with G6PD siRNA. **p<.01 vs. scramble siRNA group. (E) G6PD siRNA attenuates the upregulation of NADPH when treated with TLQP-21. **p<.01 vs. scramble siRNA group. All data were collected from three independent experiments and are presented as the mean ±SD.
    G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/g6pd/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    g6pd - by Bioz Stars, 2023-11
    95/100 stars

    Images

    1) Product Images from "TLQP-21 Protects Human Umbilical Vein Endothelial Cells against High-Glucose-Induced Apoptosis by Increasing G6PD Expression"

    Article Title: TLQP-21 Protects Human Umbilical Vein Endothelial Cells against High-Glucose-Induced Apoptosis by Increasing G6PD Expression

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0079760

    (A) G6PD activity of HUVECs with different treatments. **p<.01 vs. NC group. (B) mRNA level of G6PD with different treatments. **p<.01 vs. NC group (C) Western-blot analysis shows that G6PD expression decreased with G6PD siRNA. (D) G6PD activity decreases with G6PD siRNA. **p<.01 vs. scramble siRNA group. (E) G6PD siRNA attenuates the upregulation of NADPH when treated with TLQP-21. **p<.01 vs. scramble siRNA group. All data were collected from three independent experiments and are presented as the mean ±SD.
    Figure Legend Snippet: (A) G6PD activity of HUVECs with different treatments. **p<.01 vs. NC group. (B) mRNA level of G6PD with different treatments. **p<.01 vs. NC group (C) Western-blot analysis shows that G6PD expression decreased with G6PD siRNA. (D) G6PD activity decreases with G6PD siRNA. **p<.01 vs. scramble siRNA group. (E) G6PD siRNA attenuates the upregulation of NADPH when treated with TLQP-21. **p<.01 vs. scramble siRNA group. All data were collected from three independent experiments and are presented as the mean ±SD.

    Techniques Used: Activity Assay, Western Blot, Expressing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc anti glucose 6 phosphate dehydrogenase
    Anti Glucose 6 Phosphate Dehydrogenase, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti glucose 6 phosphate dehydrogenase/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti glucose 6 phosphate dehydrogenase - by Bioz Stars, 2023-11
    86/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc glucose 6 phosphate dehydrogenase
    Metabolic reprogramming in Lal -/- Ly6G + cells. (A) The tSNE plot of genes involved in glycolysis in Lal -/- versus Lal +/+ Ly6G + cells. (B) The tSNE plot of genes involved in the citrate cycle in Lal -/- versus Lal +/+ Ly6G + cells. (C) The tSNE plot of genes responding to ROS in Lal -/- versus Lal +/+ Ly6G + cells. In (A), (B) and (C), green dots represent cluster 123, red dots represent cluster 0468, and blue dots represent other clusters. (D) Expressions of metabolic enzymes in Lal -/- versus Lal +/+ Ly6G + cells by western blot analysis. (E) Levels of glucose, pyruvate, and α-ketoglutarate in Lal -/- versus Lal +/+ Ly6G + cells. Data are expressed as mean±SD; experiments were independently repeated, n=4. *p<0.05, **p<0.01. <t>G6PD,</t> <t>glucose-6-phosphate</t> dehydrogenase; GLUD, glutamate dehydrogenase; HK, hexokinase; KO, knockout; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; tSNE, T-stochastic neighbor embedding; WT, wild type.
    Glucose 6 Phosphate Dehydrogenase, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glucose 6 phosphate dehydrogenase/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glucose 6 phosphate dehydrogenase - by Bioz Stars, 2023-11
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti g6pd
    Dampened expression of glucose-6-phosphate dehydrogenase <t>(G6PD)</t> impairs spontaneous recovery of glutathione oxidation and NADPH following ISOPOOH exposure of HAEC. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD KD HAEC expressing Grx1-roGFP2 (A) or iNAP1 (B). G6PD KD HAEC were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 5–6 independent experiments where the responses from 10 individual cells were averaged for each experiment.
    Anti G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti g6pd/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti g6pd - by Bioz Stars, 2023-11
    95/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc 8866s
    Antibody list
    8866s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/8866s/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    8866s - by Bioz Stars, 2023-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc g6pd
    Gossypol enhances cisplatin sensitivity through inhibition of <t>NRF2/G6PD</t> axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).
    G6pd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/g6pd/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    g6pd - by Bioz Stars, 2023-11
    94/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc glucose 6 phosphate dehydrogenase activity assay kit
    Gossypol enhances cisplatin sensitivity through inhibition of <t>NRF2/G6PD</t> axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).
    Glucose 6 Phosphate Dehydrogenase Activity Assay Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glucose 6 phosphate dehydrogenase activity assay kit/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glucose 6 phosphate dehydrogenase activity assay kit - by Bioz Stars, 2023-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    Metabolic reprogramming in Lal -/- Ly6G + cells. (A) The tSNE plot of genes involved in glycolysis in Lal -/- versus Lal +/+ Ly6G + cells. (B) The tSNE plot of genes involved in the citrate cycle in Lal -/- versus Lal +/+ Ly6G + cells. (C) The tSNE plot of genes responding to ROS in Lal -/- versus Lal +/+ Ly6G + cells. In (A), (B) and (C), green dots represent cluster 123, red dots represent cluster 0468, and blue dots represent other clusters. (D) Expressions of metabolic enzymes in Lal -/- versus Lal +/+ Ly6G + cells by western blot analysis. (E) Levels of glucose, pyruvate, and α-ketoglutarate in Lal -/- versus Lal +/+ Ly6G + cells. Data are expressed as mean±SD; experiments were independently repeated, n=4. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; HK, hexokinase; KO, knockout; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; tSNE, T-stochastic neighbor embedding; WT, wild type.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

    doi: 10.1136/jitc-2022-006272

    Figure Lengend Snippet: Metabolic reprogramming in Lal -/- Ly6G + cells. (A) The tSNE plot of genes involved in glycolysis in Lal -/- versus Lal +/+ Ly6G + cells. (B) The tSNE plot of genes involved in the citrate cycle in Lal -/- versus Lal +/+ Ly6G + cells. (C) The tSNE plot of genes responding to ROS in Lal -/- versus Lal +/+ Ly6G + cells. In (A), (B) and (C), green dots represent cluster 123, red dots represent cluster 0468, and blue dots represent other clusters. (D) Expressions of metabolic enzymes in Lal -/- versus Lal +/+ Ly6G + cells by western blot analysis. (E) Levels of glucose, pyruvate, and α-ketoglutarate in Lal -/- versus Lal +/+ Ly6G + cells. Data are expressed as mean±SD; experiments were independently repeated, n=4. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; HK, hexokinase; KO, knockout; LDHA, lactate dehydrogenase A; LDHB, lactate dehydrogenase B; MDSC, myeloid-derived suppressor cell; ROS, reactive oxygen species; tSNE, T-stochastic neighbor embedding; WT, wild type.

    Article Snippet: Western blot analysis was performed as previously described using antibodies against hexokinase 1 (HK1), HK2, HK3, glucose-6-phosphate dehydrogenase (G6PD), PDH, lactate dehydrogenase A (LDHA), LDHB, and glutamate dehydrogenase (GLUD) (rabbit monoclonal antibodies, 1:1000; Cell Signaling).

    Techniques: Western Blot, Knock-Out, Derivative Assay

    Expressions of metabolic enzymes in NSCLC versus healthy subjects. (A) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in the whole blood cells. (B) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC versus healthy individuals. (C) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells. (D) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC versus healthy individuals. (E) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC versus healthy individuals. Data are expressed as mean±SD; experiments were independently repeated, n=9–13. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PDH, pyruvate dehydrogenase.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

    doi: 10.1136/jitc-2022-006272

    Figure Lengend Snippet: Expressions of metabolic enzymes in NSCLC versus healthy subjects. (A) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in the whole blood cells. (B) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC versus healthy individuals. (C) A representative gating strategy of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells. (D) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC versus healthy individuals. (E) MFI and percentages of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC versus healthy individuals. Data are expressed as mean±SD; experiments were independently repeated, n=9–13. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PDH, pyruvate dehydrogenase.

    Article Snippet: Western blot analysis was performed as previously described using antibodies against hexokinase 1 (HK1), HK2, HK3, glucose-6-phosphate dehydrogenase (G6PD), PDH, lactate dehydrogenase A (LDHA), LDHB, and glutamate dehydrogenase (GLUD) (rabbit monoclonal antibodies, 1:1000; Cell Signaling).

    Techniques:

    Checkpoint inhibitor treatment. (A) Statistical analysis of percentages of PD-L1 + cells in leucocytes of patients with NSCLC before versus after treatment. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes of patients with NSCLC before versus after treatment. (C) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (D) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC before versus after treatment. (E) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (F) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC before versus after treatment. Data are expressed as mean±SD; experiments were independently repeated, n=5–9. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; PDH, pyruvate dehydrogenase.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

    doi: 10.1136/jitc-2022-006272

    Figure Lengend Snippet: Checkpoint inhibitor treatment. (A) Statistical analysis of percentages of PD-L1 + cells in leucocytes of patients with NSCLC before versus after treatment. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes of patients with NSCLC before versus after treatment. (C) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (D) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in the leucocytes of patients with NSCLC before versus after treatment. (E) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + HLA-DR - cells of patients with NSCLC before versus after treatment. (F) MFI of PDH + , G6PD + , LDH + , and GLUD + cells in blood CD11b + CD13 + HLA-DR - cells of patients with NSCLC before versus after treatment. Data are expressed as mean±SD; experiments were independently repeated, n=5–9. *p<0.05, **p<0.01. G6PD, glucose-6-phosphate dehydrogenase; GLUD, glutamate dehydrogenase; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand-1; PDH, pyruvate dehydrogenase.

    Article Snippet: Western blot analysis was performed as previously described using antibodies against hexokinase 1 (HK1), HK2, HK3, glucose-6-phosphate dehydrogenase (G6PD), PDH, lactate dehydrogenase A (LDHA), LDHB, and glutamate dehydrogenase (GLUD) (rabbit monoclonal antibodies, 1:1000; Cell Signaling).

    Techniques:

    Dampened expression of glucose-6-phosphate dehydrogenase (G6PD) impairs spontaneous recovery of glutathione oxidation and NADPH following ISOPOOH exposure of HAEC. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD KD HAEC expressing Grx1-roGFP2 (A) or iNAP1 (B). G6PD KD HAEC were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 5–6 independent experiments where the responses from 10 individual cells were averaged for each experiment.

    Journal: Redox Biology

    Article Title: Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide

    doi: 10.1016/j.redox.2023.102646

    Figure Lengend Snippet: Dampened expression of glucose-6-phosphate dehydrogenase (G6PD) impairs spontaneous recovery of glutathione oxidation and NADPH following ISOPOOH exposure of HAEC. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD KD HAEC expressing Grx1-roGFP2 (A) or iNAP1 (B). G6PD KD HAEC were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 5–6 independent experiments where the responses from 10 individual cells were averaged for each experiment.

    Article Snippet: Electrophoresed proteins were electrotransferred onto nitrocellulose, and the blots were blocked with 5% BSA in 1X tris-buffered saline containing 0.1% tween-20 (TBST) at 4 °C for 1 h. Blots were incubated overnight at 4 °C with an anti-G6PD (Cell Signaling Technology; Danvers, MA, USA; cat# D5D2) monoclonal antibody (1:1000) in TBST containing 5% BSA.

    Techniques: Expressing, Confocal Microscopy, Incubation, Fluorescence

    Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 and iNAP1 signal in glucose deprived  G6PD  KD HAEC as shown in <xref ref-type= Fig. 5 A and B, respectively." width="100%" height="100%">

    Journal: Redox Biology

    Article Title: Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide

    doi: 10.1016/j.redox.2023.102646

    Figure Lengend Snippet: Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 and iNAP1 signal in glucose deprived G6PD KD HAEC as shown in Fig. 5 A and B, respectively.

    Article Snippet: Electrophoresed proteins were electrotransferred onto nitrocellulose, and the blots were blocked with 5% BSA in 1X tris-buffered saline containing 0.1% tween-20 (TBST) at 4 °C for 1 h. Blots were incubated overnight at 4 °C with an anti-G6PD (Cell Signaling Technology; Danvers, MA, USA; cat# D5D2) monoclonal antibody (1:1000) in TBST containing 5% BSA.

    Techniques:

    A knockout of glucose-6-phosphate dehydrogenase (G6PD) in a BALB/c cell model impairs glucose-mediated recovery of glutathione oxidation following ISOPOOH exposure. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD knockout (A, C) or wild-type BALB/c cells (B, D), respectively. BALB/c cells expressing Grx1-roGFP2 (A, B) or iNAP1 (C, D) were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 3–5 independent experiments where the responses from 10 individual cells were averaged for each experiment.

    Journal: Redox Biology

    Article Title: Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide

    doi: 10.1016/j.redox.2023.102646

    Figure Lengend Snippet: A knockout of glucose-6-phosphate dehydrogenase (G6PD) in a BALB/c cell model impairs glucose-mediated recovery of glutathione oxidation following ISOPOOH exposure. The ratio of oxidized glutathione to reduced glutathione (GSSG:GSH) and NADPH flux was monitored using live cell confocal microscopy of G6PD knockout (A, C) or wild-type BALB/c cells (B, D), respectively. BALB/c cells expressing Grx1-roGFP2 (A, B) or iNAP1 (C, D) were pre incubated in glucose deficient medium for 2 h prior to exposure to 1–9 μM ISOPOOH. Following the acquisition of a baseline signal, vehicle, 1–9 μM ISOPOOH, and 1 mM glucose were added at the indicated times. Emitted fluorescence intensity values are shown normalized to their respective baselines and expressed as the ratio of signal induced by 405/488 nm excitation. Data are expressed as MEAN ± SEM for n = 3–5 independent experiments where the responses from 10 individual cells were averaged for each experiment.

    Article Snippet: Electrophoresed proteins were electrotransferred onto nitrocellulose, and the blots were blocked with 5% BSA in 1X tris-buffered saline containing 0.1% tween-20 (TBST) at 4 °C for 1 h. Blots were incubated overnight at 4 °C with an anti-G6PD (Cell Signaling Technology; Danvers, MA, USA; cat# D5D2) monoclonal antibody (1:1000) in TBST containing 5% BSA.

    Techniques: Knock-Out, Confocal Microscopy, Expressing, Incubation, Fluorescence

    Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 signal in glucose deprived  G6PD  KO BALB/c and WT BALB/c cells as shown in <xref ref-type= Fig. 6 A and B, respectively." width="100%" height="100%">

    Journal: Redox Biology

    Article Title: Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide

    doi: 10.1016/j.redox.2023.102646

    Figure Lengend Snippet: Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in Grx1-roGFP2 signal in glucose deprived G6PD KO BALB/c and WT BALB/c cells as shown in Fig. 6 A and B, respectively.

    Article Snippet: Electrophoresed proteins were electrotransferred onto nitrocellulose, and the blots were blocked with 5% BSA in 1X tris-buffered saline containing 0.1% tween-20 (TBST) at 4 °C for 1 h. Blots were incubated overnight at 4 °C with an anti-G6PD (Cell Signaling Technology; Danvers, MA, USA; cat# D5D2) monoclonal antibody (1:1000) in TBST containing 5% BSA.

    Techniques:

    Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in iNAP1 signal in glucose deprived  G6PD  KO BALB/c and WT BALB/c cells as shown in <xref ref-type= Fig. 6 C and D, respectively." width="100%" height="100%">

    Journal: Redox Biology

    Article Title: Real-time redox adaptations in human airway epithelial cells exposed to isoprene hydroxy hydroperoxide

    doi: 10.1016/j.redox.2023.102646

    Figure Lengend Snippet: Linear regression analysis of ISOPOOH-induced and glucose-mediated changes in iNAP1 signal in glucose deprived G6PD KO BALB/c and WT BALB/c cells as shown in Fig. 6 C and D, respectively.

    Article Snippet: Electrophoresed proteins were electrotransferred onto nitrocellulose, and the blots were blocked with 5% BSA in 1X tris-buffered saline containing 0.1% tween-20 (TBST) at 4 °C for 1 h. Blots were incubated overnight at 4 °C with an anti-G6PD (Cell Signaling Technology; Danvers, MA, USA; cat# D5D2) monoclonal antibody (1:1000) in TBST containing 5% BSA.

    Techniques:

    Antibody list

    Journal: Journal of Food and Drug Analysis

    Article Title: A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells

    doi: 10.38212/2224-6614.3376

    Figure Lengend Snippet: Antibody list

    Article Snippet: G6PD , Immunoblot , rabbit , 8866S (Cell Signaling Technology).

    Techniques: Western Blot

    Gossypol enhances cisplatin sensitivity through inhibition of NRF2/G6PD axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).

    Journal: Journal of Food and Drug Analysis

    Article Title: A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells

    doi: 10.38212/2224-6614.3376

    Figure Lengend Snippet: Gossypol enhances cisplatin sensitivity through inhibition of NRF2/G6PD axis in cisplatin resistant HNSCC cells. (A) The box plot of G6PD expression in different cancer cell lines. The expression levels of G6PD in cisplatin-resistant (left plot) and cisplatin-sensitive cancer cells (right plot) were retrieved from the Oncomine database. (B) Dose-dependent effect of gossypol on protein levels of NRF2, G6PD and NQO1. After treatment with 0.625, 1.25, 2.5, and 5 μM of gossypol for 24 h, the expression levels of NRF2, G6PD and NQO1 proteins were detected by Western blot analysis. β-Actin was used as the internal control. (C) The IC 50 values of cisplatin in parental HONE-1 cell and the two resistant sub-lines, cis6 and cis15. The Resistance Index was calculated by dividing the IC 50 value of cisplatin in resistant sub-line by the IC 50 value of cisplatin in parental HONE-1 cell. (D) Total and phospho-NRF2 levels in parental and cisplatin-resistant HONE-1 cells. β-Actin was used as the internal control. (E ~ G) Cytotoxicity effects of gossypol combined with cisplatin in HONE-1-derieved cells. The cells were co-treated with non-toxic concentration of gossypol (0.5 μM) with cisplatin for 72 h, and cell viability was determined by methylene blue assays (E: parental HONE-1 cells; F: cisplatin-resistant cis6 cells; G: cisplatin-resistant cis15 cells).

    Article Snippet: G6PD , Immunoblot , rabbit , 8866S (Cell Signaling Technology).

    Techniques: Inhibition, Expressing, Western Blot, Concentration Assay

    Antibody list

    Journal: Journal of Food and Drug Analysis

    Article Title: A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells

    doi: 10.38212/2224-6614.3376

    Figure Lengend Snippet: Antibody list

    Article Snippet: G6PD , Immunoblot , rabbit , 8866S (Cell Signaling Technology).

    Techniques: Western Blot